Mode
Text Size
Log in / Sign up

MRI Radiomics Predicts TERTp Mutation in Glioma with Moderate AccuracyMRI Radiomics Help Predict TERTp Mutation in Glioma Patients

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
MRI radiomics predicts TERTp mutation in glioma with moderate accuracy; combined models show numerical improvement but evidence is limited.

This systematic review and meta-analysis evaluated the diagnostic accuracy of pre-operative MRI-based radiomics for predicting telomerase reverse transcriptase promoter (TERTp) mutation status in patients with glioma. Fourteen studies comprising 2,863 patients were included, with 13 studies contributing to quantitative meta-analysis.

The pooled sensitivity and specificity of MRI-only radiomics models were 0.76 (95% CI, 0.66-0.84) and 0.70 (95% CI, 0.63-0.77), respectively, with an area under the curve (AUC) of 0.79 (95% CI, 0.75-0.82). Clinical-only models showed lower specificity (0.57; 95% CI, 0.34-0.77) and AUC (0.73; 95% CI, 0.69-0.77). Combined radiomics-clinical models demonstrated numerically higher performance, with sensitivity 0.78 (95% CI, 0.70-0.85), specificity 0.76 (95% CI, 0.67-0.84), and AUC 0.82 (95% CI, 0.79-0.85).

However, the evidence is limited by retrospective designs, internal validation only, and methodological heterogeneity across studies. The findings suggest that MRI radiomics offers moderate accuracy for non-invasive prediction of TERTp status, and combining radiomics with clinical features may provide incremental benefit. These models should be considered adjunctive tools rather than replacements for histopathological assessment.

How this fits prior evidence

This meta-analysis addresses a gap in identifying non-invasive biomarkers for TERTp mutation status in glioma. While previous evidence has explored deep learning for glioma segmentation and the role of metabolic-immune axes in progression, this study specifically evaluates radiomics as a diagnostic tool for genetic markers. It complements existing research on imaging parameters like NODI by providing an additional layer of predictive modeling for molecular characteristics.

Researchers analyzed data from 2,863 patients with glioma to see if pre-operative MRI scans could identify a specific genetic marker called TERTp mutation. They compared three different methods: using only clinical information, using only MRI radiomics (advanced image analysis), and combining both types of data.

The study found that MRI radiomics alone showed moderate accuracy in predicting the mutation. However, when doctors combined MRI radiomics with standard clinical information, the prediction became more accurate. These results suggest that advanced imaging tools can provide useful additional information for doctors managing glioma cases.

Because this research relied on older data and varied methods across different studies, the findings should be viewed as a helpful tool rather than a definitive replacement for current medical decisions. Patients should discuss these emerging imaging technologies with their oncology team to see how they might fit into their specific care plan.

What this means for you:
MRI radiomics can help predict TERTp mutations in glioma, especially when combined with clinical data.

Common questions

What is the role of MRI radiomics in glioma diagnosis?

MRI radiomics involves using advanced analysis of pre-operative scans to predict specific genetic markers like TERTp mutations. The study found that these models have a moderate accuracy, with an AUC of 0.79. These tools are intended to be used alongside traditional clinical methods to provide more information for doctors.

Is combining MRI data with clinical info better?

Yes, the study found that combined radiomics-clinical models were numerically superior to using either method alone. Specifically, the combined model had a higher AUC of 0.82 compared to 0.79 for radiomics-only and 0.73 for clinical-only models when predicting TERTp mutation status.

How accurate are these prediction models?

The models show moderate accuracy for identifying mutations. The MRI-only model had a sensitivity of 0.76 and specificity of 0.70. The combined model showed even higher results, with a sensitivity of 0.78 and specificity of 0.76. These findings are currently considered descriptive tools rather than definitive replacements.

Study Details

Study typeMeta analysis
Sample sizen = 2,863
EvidenceLevel 1
PublishedJun 2026
View Original Abstract ↓
TERT promoter (TERTp) mutations shape glioma prognosis and therapy, yet tissue testing can be limited by sampling error and surgical inaccessibility. MRI-based radiomics offers a non-invasive alternative. This study aimed to quantify the diagnostic accuracy of pre-operative MRI radiomics for predicting TERTp status and compare radiomics-only, clinical-only, and combined models.We conducted a PRISMA-DTA-conformant, PROSPERO-registered systematic review and meta-analysis. PubMed, Embase, Web of Science, and Scopus were searched to 13 October 2025. Eligible studies evaluated MRI-derived radiomics models and reported accuracy on non-training data against a molecular reference standard. Risk of bias was appraised with QUADAS-AI. Bivariate random-effects models pooled sensitivity, specificity, and AUC, prioritizing external test performance when available. Fourteen retrospective studies including 2,863 patients were eligible for systematic review; 13 studies were included in the quantitative meta-analysis. MRI-only radiomics models demonstrated pooled sensitivity of 0.76 (95% CI, 0.66-0.84), specificity of 0.70 (95% CI, 0.63-0.77), and AUC of 0.79 (95% CI, 0.75-0.82), indicating moderate discriminative performance with substantial heterogeneity. Deeks' funnel plot asymmetry test was not significant (p = 0.78). Clinical-only models yielded pooled sensitivity of 0.73 (95% CI, 0.61-0.82), specificity of 0.57 (95% CI, 0.34-0.77), and AUC of 0.73 (95% CI, 0.69-0.77). Combined radiomics-clinical models showed numerically higher pooled performance, with sensitivity of 0.78 (95% CI, 0.70-0.85), specificity of 0.76 (95% CI, 0.67-0.84), and AUC of 0.82 (95% CI, 0.79-0.85), although this finding should be interpreted descriptively rather than as definitive evidence of superiority. Subgroup analyses suggested that classifier type, validation strategy, and feature-extraction software may contribute to performance variability. Sensitivity analysis showed that the overall findings remained broadly stable after excluding the influential study. Pre-operative MRI-based radiomics shows moderate accuracy for predicting TERTp mutation status in glioma. Combined radiomics-clinical models achieved numerically higher performance, but current evidence remains limited by retrospective designs, internal validation, and methodological heterogeneity. These models should be considered adjunctive rather than replacement tools, and prospective multicenter external validation with standardized workflows is required before clinical implementation.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.